HOOKIPA to Present at the SVB Leerink Global Healthcare Conference
February 09, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
January 18, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation...
HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference
January 04, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit
December 03, 2021 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtual Healthcare Conference
November 12, 2021 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
November 10, 2021 06:30 ET
|
HOOKIPA Pharma Inc.
Clinical collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, set to evaluate HB-201 in combination with pembrolizumab in 1st- and 2nd-line HNSCC patientsBased on recent strong data updates,...
HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform
November 09, 2021 16:01 ET
|
HOOKIPA Pharma Inc.
Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combination with pembrolizumab in 1st and 2nd line head and neck cancerInterim Phase 1 HB-200 data continue...
HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
November 03, 2021 08:18 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology
October 14, 2021 07:00 ET
|
HOOKIPA Pharma Inc.
Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immunotherapy strategy to address critical unmet needs in cancerPre-clinical and clinical data showcase...
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers
September 15, 2021 07:00 ET
|
HOOKIPA Pharma Inc.
Clinical collaboration to assess HB-200 in combination with KEYTRUDA® (pembrolizumab) as first-line treatmentHOOKIPA poised to advance clinical development program with randomized Phase 2 study in...